Jane Street’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $376K | Sell |
17,300
-29,200
| -63% | -$565K | ﹤0.01% | 8707 |
|
|
2025
Q4 | $1M | Sell |
46,500
-27,100
| -37% | -$571K | ﹤0.01% | 6116 |
|
|
2025
Q3 | $1.42M | Sell |
73,600
-378,600
| -84% | -$6.75M | ﹤0.01% | 5583 |
|
|
2025
Q2 | $7.73M | Buy |
452,200
+287,600
| +175% | +$12.3M | ﹤0.01% | 2462 |
|
|
2025
Q1 | $10.5M | Buy |
164,600
+27,700
| +20% | +$2.92M | ﹤0.01% | 1932 |
|
|
2024
Q4 | $16.6M | Sell |
136,900
-17,100
| -11% | -$2.1M | ﹤0.01% | 1418 |
|
|
2024
Q3 | $19.2M | Buy |
154,000
+600
| +0.4% | +$82.9K | ﹤0.01% | 1269 |
|
|
2024
Q2 | $24.2M | Buy |
153,400
+13,800
| +10% | +$1.77M | 0.01% | 1161 |
|
|
2024
Q1 | $18.1M | Sell |
139,600
-63,400
| -31% | -$7.77M | ﹤0.01% | 1278 |
|
|
2023
Q4 | $19.6M | Buy |
203,000
+118,000
| +139% | +$11.3M | 0.01% | 1284 |
|
|
2023
Q3 | $10.3M | Sell |
85,000
-30,500
| -26% | -$3.45M | ﹤0.01% | 1736 |
|
|
2023
Q2 | $13.2M | Sell |
115,500
-114,200
| -50% | -$14.7M | ﹤0.01% | 1618 |
|
|
2023
Q1 | $31.7M | Buy |
229,700
+166,500
| +263% | +$21.6M | 0.01% | 716 |
|
|
2022
Q4 | $8.19M | Buy |
63,200
+14,900
| +31% | +$1.73M | ﹤0.01% | 1843 |
|
|
2022
Q3 | $5.34M | Buy |
48,300
+33,000
| +216% | +$3.33M | ﹤0.01% | 2515 |
|
|
2022
Q2 | $1.15M | Sell |
15,300
-24,400
| -61% | -$1.8M | ﹤0.01% | 5234 |
|
|
2022
Q1 | $3.1M | Sell |
39,700
-39,400
| -50% | -$3.02M | ﹤0.01% | 3882 |
|
|
2021
Q4 | $7.12M | Buy |
79,100
+14,200
| +22% | +$1.21M | ﹤0.01% | 2330 |
|
|
2021
Q3 | $6M | Buy |
64,900
+2,700
| +4% | +$208K | ﹤0.01% | 2469 |
|
|
2021
Q2 | $4.83M | Sell |
62,200
-157,200
| -72% | -$11.9M | ﹤0.01% | 2699 |
|
|
2021
Q1 | $16.4M | Buy |
219,400
+43,800
| +25% | +$4.04M | 0.01% | 1145 |
|
|
2020
Q4 | $29.9M | Sell |
175,600
-49,100
| -22% | -$7.28M | 0.02% | 650 |
|
|
2020
Q3 | $31.6M | Buy |
224,700
+171,900
| +326% | +$26.1M | 0.02% | 564 |
|
|
2020
Q2 | $8.47M | Buy |
52,800
+47,300
| +860% | +$6.44M | 0.01% | 1315 |
|
|
2020
Q1 | $538K | Sell |
5,500
-34,800
| -86% | -$3.98M | ﹤0.01% | 3553 |
|
|
2019
Q4 | $5.2M | Sell |
40,300
-1,700
| -4% | -$172K | 0.01% | 1059 |
|
|
2019
Q3 | $3.16M | Buy |
42,000
+6,200
| +17% | +$732K | 0.01% | 1349 |
|
|
2019
Q2 | $5.44M | Buy |
35,800
+9,000
| +34% | +$1.09M | 0.01% | 985 |
|
|
2019
Q1 | $3.19M | Buy |
26,800
+24,000
| +857% | +$3.09M | 0.01% | 1529 |
|
|
2018
Q4 | $306K | Buy |
+2,800
| New | +$350K | ﹤0.01% | 4043 |
|
|
2018
Q3 | – | Sell |
-109,300
| Closed | -$14.4M | – | 5677 |
|
|
2018
Q2 | $14.4M | Buy |
109,300
+105,000
| +2,442% | +$9.9M | 0.03% | 433 |
|
|
2018
Q1 | $319K | Sell |
4,300
-5,300
| -55% | -$353K | ﹤0.01% | 3946 |
|
|
2017
Q4 | $534K | Sell |
9,600
-200
| -2% | -$10.6K | ﹤0.01% | 3093 |
|
|
2017
Q3 | $445K | Sell |
9,800
-800
| -8% | -$32K | ﹤0.01% | 3253 |
|
|
2017
Q2 | $357K | Buy |
+10,600
| New | +$345K | ﹤0.01% | 3412 |
|
|
2017
Q1 | – | Sell |
-12,700
| Closed | -$348K | – | 4648 |
|
|
2016
Q4 | $348K | Sell |
12,700
-65,600
| -84% | -$2.63M | ﹤0.01% | 3209 |
|
|
2016
Q3 | $4.81M | Buy |
78,300
+8,700
| +13% | +$263K | 0.02% | 611 |
|
|
2016
Q2 | $1.33M | Sell |
69,600
-40,000
| -36% | -$741K | 0.01% | 1679 |
|
|
2016
Q1 | $2.14M | Buy |
109,600
+103,500
| +1,697% | +$1.81M | 0.01% | 1118 |
|
|
2015
Q4 | $235K | Buy |
+6,100
| New | +$198K | ﹤0.01% | 3394 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Jane Street's SRPT Position: Q1 2026 in Review
Jane Street opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 187,709 shares worth $4.08M. The stake represents ﹤0.01% of the portfolio and ranks #3813 among its holdings. This is a return to the name: Jane Street previously reported a position in SRPT as recently as Q2 2025.
Jane Street first reported a position in SRPT in Q2 2013 and has held it in 45 quarters since. The position peaked at $137M in Q2 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Jane Street held 187,709 shares of Sarepta Therapeutics worth $4.08M as of Q1 2026.
- Sarepta Therapeutics was a new Jane Street position in Q1 2026.
- Sarepta Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3813 holding.
- Jane Street first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 45 quarters since.
- Jane Street's Sarepta Therapeutics position peaked at $137M in Q2 2024.
- 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.